A prospective, single arm, investigator initiated clinical study to assess the safety and performance of Cross-linked Hyaluronic Acid- Dermal filler(JEUNESSO 20L) in people with all skin types, who need Lip Enhancement, Cheek bone Augmentation and Nasolabial fold improvement.

Dr. Hemant Talanikar0 个研究点目标入组 122 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1. At risk in term of precautions, warnings and contra indication referred in the package insert of the study
•dermal filler
•2. Who underwent previous injection of permanent filler in
•the injected area
•3. Pregnant/lactating women
•4. Participation in any other Clinical trial.
•5. Subjects who have an allergy to lidocaine, prilocaine or
•other amide-type anesthetic
•6. Had a chemical peel at the Nasolabial Fold (NLF) area
•within 4 weeks prior to study entry. In addition, subjects
•were restricted from undergoing chemical peels at the
•Nasolabial Fold (NLF) area for the duration of the study
•8. Had a history of hypo- or hyperpigmentation of the skin.
•9. Inolerance to antibiotics or corticosteroids.
•10. Had any infection, unhealed wound, or active
•inflammatory process (e.g., skin eruptions such as cysts,
•pimples, rashes, or hives) at the injection site(s).
•11. A known history of keloids or bleeding disorders.
•12. Leukoderma (Vitiligo) or a family history of leukoderma
•or other pigmentary disorders.
•13. Patient on Medication with blood thinners.
•14. Severe physical, neurological or mental disease.
•15. Excessive facial hair that might interfere with the study
•of the wrinkle assessments

发起方

Dr. Hemant Talanikar